Alteogen enters obesity drug race with once-monthly platform technology

Alteogen, the biotech company that built a multibillion-dollar technology export record with its human hyaluronidase platform (ALT-B4) for converting intravenous drugs into subcutaneous formulations, has formally entered the obesity treatment market — the pharmaceutical industry's most fiercely contested arena.

The company is going beyond simple pipeline development, leading with a new platform designed to extend drug duration and simultaneously address two of the biggest weaknesses of existing blockbuster obesity drugs: dosing frequency and post-treatment weight rebound.

According to industry sources Friday, Alteogen has completed an international patent application (PCT) for its proprietary Long-Acting Conjugate platform, which extends a drug's duration of action by combining multiple active molecules, and has begun developing ALT-M5, its first obesity treatment candidate based on the technology.

The platform builds on existing antibody conjugation technology to extend a drug's half-life in the body, with the core design goal of enabling once-monthly dosing.

The global obesity drug market is currently dominated — by more than 90 percent — by once-weekly subcutaneous injection formulations, led by Novo Nordisk's Wegovy and Eli Lilly's Zepbound. Two persistent limitations remain: the burden of weekly injections and the sharp rebound in body weight, commonly known as the yo-yo effect, that occurs when patients stop treatment.

As a result, the global development race is rapidly shifting toward ultra-long-acting formulations that dramatically extend the dosing interval. Amgen is advancing its once-monthly candidate MariTide through late-stage clinical trials, and other major pharmaceutical companies including Pfizer are also racing to develop once-monthly formulations.

Alteogen has selected ALT-M5, a once-monthly obesity treatment candidate, as the first pipeline to use the new platform. The company highlighted animal study results showing both the feasibility of once-monthly dosing and the ability to suppress weight regain after treatment stops. If the multi-molecule conjugation technology can control the sharp appetite rebound that occurs as drug efficacy gradually wanes, ALT-M5 could become a strong alternative that overcomes the chronic limitations of existing treatments.

Industry observers say the move marks a turning point that could diversify Alteogen's corporate value structure. Market attention has long been concentrated on the company's hyaluronidase-based subcutaneous injection platform (ALT-B4), but the new technology can be extended beyond obesity to a wide range of peptide and protein biopharmaceuticals.

Alteogen plans to formally present ALT-M5's weight-regain suppression research findings at ObesityWeek 2026, scheduled for Nov. 14-17 in Washington, D.C., and to begin demonstrating its technology's competitiveness to global pharmaceutical companies.

"This patented technology is a platform that can be applied to a wide range of biopharmaceuticals to create once-monthly dosing formulations," said Jeon Tae-yeon, chief executive of Alteogen. "Building on the ALT-M5 animal study results, we will develop a differentiated obesity treatment that addresses the unmet needs of once-monthly dosing and weight regain after discontinuation."